Illumina, Inc. $ILMN Shares Purchased by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership raised its holdings in Illumina, Inc. (NASDAQ:ILMN) by 81.0% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 334,791 shares of the life sciences company’s stock after acquiring an additional 149,801 shares during the period. Arrowstreet Capital Limited Partnership owned approximately 0.22% of Illumina worth $31,942,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. boosted its holdings in shares of Illumina by 3.5% during the 1st quarter. Vanguard Group Inc. now owns 16,371,662 shares of the life sciences company’s stock worth $1,298,928,000 after purchasing an additional 558,243 shares during the last quarter. WCM Investment Management LLC increased its holdings in shares of Illumina by 5.9% in the second quarter. WCM Investment Management LLC now owns 4,426,471 shares of the life sciences company’s stock valued at $419,585,000 after purchasing an additional 247,460 shares during the last quarter. Loomis Sayles & Co. L P lifted its position in Illumina by 1.9% during the second quarter. Loomis Sayles & Co. L P now owns 4,225,529 shares of the life sciences company’s stock worth $403,158,000 after buying an additional 78,317 shares in the last quarter. Corvex Management LP boosted its stake in Illumina by 125.2% during the first quarter. Corvex Management LP now owns 3,829,608 shares of the life sciences company’s stock worth $303,841,000 after buying an additional 2,129,449 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in Illumina by 0.7% in the 2nd quarter. Geode Capital Management LLC now owns 2,869,187 shares of the life sciences company’s stock valued at $272,921,000 after buying an additional 21,342 shares in the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Illumina

In related news, Director Scott Gottlieb bought 500 shares of the company’s stock in a transaction that occurred on Monday, November 3rd. The stock was purchased at an average price of $122.13 per share, for a total transaction of $61,065.00. Following the acquisition, the director owned 12,523 shares of the company’s stock, valued at approximately $1,529,433.99. This trade represents a 4.16% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 2.60% of the company’s stock.

Analyst Ratings Changes

ILMN has been the subject of a number of recent research reports. TD Cowen raised their target price on Illumina from $110.00 to $115.00 and gave the stock a “hold” rating in a research note on Friday, October 31st. Wall Street Zen raised shares of Illumina from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Weiss Ratings restated a “hold (c-)” rating on shares of Illumina in a research report on Thursday. Canaccord Genuity Group boosted their target price on shares of Illumina from $105.00 to $112.00 and gave the company a “hold” rating in a report on Friday, October 31st. Finally, Evercore ISI increased their price target on shares of Illumina from $132.00 to $142.00 and gave the company an “outperform” rating in a research note on Friday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, thirteen have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $115.00.

Illumina Stock Up 0.7%

Shares of ILMN opened at $128.96 on Friday. The company’s 50-day moving average price is $111.21 and its 200 day moving average price is $100.92. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $153.06. The company has a current ratio of 1.43, a quick ratio of 1.12 and a debt-to-equity ratio of 0.42. The firm has a market cap of $19.71 billion, a P/E ratio of 28.91, a price-to-earnings-growth ratio of 2.31 and a beta of 1.44.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.16 by $0.18. The company had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.07 billion. Illumina had a net margin of 16.40% and a return on equity of 29.21%. Illumina’s revenue was up .4% compared to the same quarter last year. During the same quarter last year, the firm posted $1.14 earnings per share. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. On average, sell-side analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.